Why the study?
Polycystic ovary syndrome is a heterogeneous disorder with a lack of clear presentation, leading to a prolonged diagnostic process.
Do bile acids and FGF-21 improve early detection of PCOS in women with obesity?
Observational
Do bile acids and FGF-21 improve early detection of PCOS in women with obesity?
Bile acids and FGF-21 are elevated in obese women with PCOS, suggesting their potential utility as novel diagnostic biomarkers.
Answers are grounded in this paper and cite their sources.
Bile acid profiling may aid earlier PCOS detection; leaves open diagnostic utility pending validation in larger cohorts.
Objective: Polycystic ovary syndrome (PCOS) is a heterogeneous disorder characterized by a reduction in fertility and metabolic dysfunction. Unfortunately, due to a lack of clear presentation, it is often a long process of diagnosis. In this study, we investigated bile acids as potential biomarkers. Materials and Methods: Subjects were recruited and stratified into groups based on body mass index and PCOS status. Biometric data and plasma were acquired to understand bile acid profiles and related markers. Results: Taurocholic acid (TCA) and taurodeoxycholic acid were elevated in PCOS subjects with obesity in comparison to controls without PCOS. Fibroblast growth factor 21 (FGF-21), a metabolic regulator implemented in bile acid metabolism, was elevated in PCOS patients and was positively correlated with TCA changes. Conclusions: We present evidence suggesting that bile acids may be novel diagnostic targets in obese patients with PCOS while further studies need to delineate the interplay between FGF-21, bile acids, and testosterone in the early detection of PCOS.
No takes yet. Share an insight, caveat, or question.
Yoost et al. (2022) conducted an observational in Polycystic ovary syndrome. Bile acids and Fibroblast Growth Factor 21 vs. Controls without PCOS was evaluated on Bile acid profiles and related markers.
Synapse has enriched 10 related papers. Consider them for comparative context: